Biologic drug adalimumab is effective in treating rheumatoid arthritis
Jul 20, 2005 - 3:07:00 PM
"The drug is relatively new and so it is not surprising that there is little data from long-term studies, but the evidence so far is encouraging," says lead author Federico Navarro-Sarabia, Chair of Rheumatology at the Hospital Universitario Virgen Macarena, Seville, Spain.
By Cochrane Library, [RxPG] There is good evidence that adding adalimumab (Humira) to the treatment of people with long-standing rheumatoid arthritis is more effective than using oral methotrexate alone.
Adalimumab is a relatively new antibody-based therapy. Patients given 24 weeks of therapy with adalimumab and methotrexate had decreased pain and swelling and an increased ability to perform normal daily activities compared with those given methotrexate alone or no disease modifying anti-rheumatic drugs (DMARDs). X-ray damage to the joints is also slowed. Side effects in the short-term are well-tolerated. Rare and long-term side effects are not yet known.
"The drug is relatively new and so it is not surprising that there is little data from long-term studies, but the evidence so far is encouraging," says lead author Federico Navarro-Sarabia, Chair of Rheumatology at the Hospital Universitario Virgen Macarena, Seville, Spain.
In the UK, the National Institute for Health and Clinical Excellence ( NICE) is currently assessing adalimumab for use in rheumatoid arthritis.
Publication:
Review Title: Navarro-Sarabia et al: Adalimumab for treating rheumatoid arthritis. The Cochrane Database of Systematic Reviews 2005 Issue 3
On the web:www.interscience.wiley.com
Advertise in this space for $10 per month.
Contact us today.
Cochrane reviews are based on the best available information about healthcare interventions. They explore the evidence for and against the effectiveness and appropriateness of treatments (medications, surgery, education, etc) in specific circumstances.
The complete reviews are published in The Cochrane Library which is available by subscription, either on CDROM or via the Internet. You should be able to browse the Cochrane Library at your nearest medical library if you don't have your own subscription.
The Cochrane Library is published four times a year. Each issue contains all existing reviews plus an increasingly wider range of new and updated reviews. It is published and distributed by Wiley InterScience and is also distributed by a number of other Distribution Partners. It is not available for sale from Cochrane Centres.
Feedback
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
